North America Biopsy Devices Market Report by Product, Application, Technology, End User, Countries and Companies Analysis 2026-2034

North America Biopsy Devices Market Size and Forecast 2026-2034

North America Biopsy Devices Market is expected to reach US$ 1,369.54 Million by 2034 from US$ 877.54 Million in 2025, with a CAGR of 5.07% from 2026 to 2034. The North America biopsy devices market is growing due to rising cancer prevalence, increasing demand for minimally invasive diagnostic procedures, expanding screening programs, and continuous technological advancements in tissue sampling devices. Growing healthcare investments and emphasis on early disease detection further support market expansion.

North America Biopsy Devices Industry Overview

Biopsy devices are specialized medical instruments used to collect tissue or cell samples from the body for diagnostic examination. These devices help physicians identify diseases such as cancer, infections, inflammatory conditions, and other abnormalities. Common biopsy techniques include needle biopsy, vacuum-assisted biopsy, core needle biopsy, fine-needle aspiration, and image-guided biopsy procedures. Modern biopsy devices are designed to improve tissue sample quality, procedural accuracy, patient comfort, and diagnostic efficiency while minimizing invasiveness. They are widely used across oncology, gastroenterology, breast care, pulmonology, urology, and neurology. Advances in imaging integration and automated sampling technologies continue to enhance biopsy procedure outcomes and diagnostic precision.

The North America biopsy devices market is witnessing substantial growth due to increasing incidence of cancer and chronic diseases requiring tissue-based diagnosis. Growing awareness regarding early disease detection and expanding adoption of minimally invasive procedures are driving demand for advanced biopsy technologies. Healthcare providers are increasingly utilizing image-guided and automated biopsy systems to improve diagnostic accuracy and reduce patient discomfort. Rising investments in oncology care, expansion of screening programs, and technological innovations in tissue acquisition devices are further strengthening market growth. Additionally, increasing demand for personalized medicine and molecular diagnostics is creating a greater need for high-quality tissue samples obtained through advanced biopsy procedures.

Recent Developments in North America Biopsy Devices Market

• In 2024, Hologic, Inc. expanded its breast health portfolio with the introduction of the Breast Biopsy Suite, a comprehensive platform that combines advanced imaging technologies with biopsy solutions to improve lesion targeting, diagnostic accuracy, and clinical workflow efficiency during breast cancer evaluations.
• In 2023, BD launched an enhanced core biopsy needle system designed to improve tissue acquisition quality and sampling precision. The innovation supports more reliable pathological assessments while helping clinicians perform minimally invasive diagnostic procedures with greater confidence.
• In 2023, Argon Medical Devices introduced a new vacuum-assisted biopsy platform aimed at improving tissue collection during minimally invasive procedures. The system was developed to enhance procedural efficiency, obtain larger tissue samples, and support accurate diagnosis across a variety of clinical applications, including oncology and breast health.

Growth Drivers for the North America Biopsy Devices Market

Rising Demand for Early Cancer Detection and Accurate Diagnostics

The increasing burden of cancer across North America continues to drive demand for advanced biopsy devices. Early diagnosis significantly improves treatment outcomes, making tissue sampling an essential component of cancer management. Healthcare providers are expanding screening initiatives for breast, lung, prostate, gastrointestinal, and pancreatic cancers, increasing the volume of biopsy procedures performed annually. In addition, the growth of precision medicine has heightened the need for high-quality tissue samples capable of supporting molecular and genomic testing.

Advancements in biopsy technology are enabling clinicians to obtain larger and more intact tissue specimens while minimizing procedural risks. Improved sampling quality supports more accurate diagnoses and personalized treatment planning.

In January 2026, Olympus announced the U.S. launch of the SecureFlex(TM) Single-Use Fine Needle Biopsy Device, designed for endoscopic ultrasound-guided tissue sampling. The device supports collection of larger tissue samples and improved access to difficult anatomical locations, particularly for pancreatic cancer diagnosis.

Growing Adoption of Minimally Invasive and Image-Guided Procedures

Healthcare providers are increasingly favoring minimally invasive diagnostic techniques that reduce patient recovery times, lower complication rates, and improve procedural efficiency. Image-guided biopsy procedures utilizing ultrasound, MRI, CT, and stereotactic technologies have become standard practice across multiple clinical specialties. These approaches allow physicians to target suspicious lesions with greater precision while minimizing trauma to surrounding tissues.

The demand for minimally invasive procedures is particularly strong in breast cancer diagnostics, where technological improvements continue to enhance workflow efficiency and patient experience. As healthcare systems focus on improving outcomes while reducing procedural burdens, advanced biopsy devices are gaining widespread acceptance.

In November 2024, Mammotome introduced the AutoCore(TM) Single Insertion Core Biopsy System, the first automated spring-loaded core needle biopsy device designed to simplify ultrasound-guided biopsy procedures and improve operational efficiency through a single-insertion design.

Technological Innovation Supporting Precision Tissue Acquisition

Continuous innovation in biopsy technologies is strengthening market growth by improving tissue acquisition quality and diagnostic reliability. Manufacturers are developing automated, motorized, and vacuum-assisted biopsy systems that provide larger and higher-quality specimens for histopathological and molecular analysis. These innovations support growing demand for precision diagnostics, particularly in oncology and gastrointestinal disease management.

The integration of advanced engineering, automation, and enhanced sampling mechanisms is enabling clinicians to perform more effective procedures while reducing the number of tissue collection attempts. Such advancements contribute to better patient outcomes and improved healthcare efficiency.

In February 2025, Limaca Medical launched the Precision-GI(TM) automated motorized EUS biopsy device in the U.S. market. The system utilizes a motorized rotating cutting mechanism designed to improve tissue sample volume and quality for gastrointestinal and pancreatic cancer diagnostics.

Challenges in the North America Biopsy Devices Market

High Procedure Costs and Capital Equipment Requirements

Advanced biopsy procedures often require sophisticated imaging systems, specialized biopsy instruments, and highly trained medical professionals. The cost of acquiring and maintaining image-guided biopsy equipment can place financial pressure on healthcare facilities, particularly smaller hospitals and outpatient centers. Additionally, reimbursement variations may affect provider adoption of newer technologies. The integration of advanced biopsy systems frequently requires staff training, workflow modifications, and ongoing maintenance expenses. While technological innovation improves diagnostic capabilities, the associated costs may limit accessibility in certain healthcare settings. Balancing technological advancement with affordability remains a key challenge for manufacturers and healthcare providers seeking to expand access to modern biopsy procedures across North America.

Procedural Risks and Diagnostic Sampling Limitations

Although biopsy procedures are generally safe, they still carry risks including bleeding, infection, tissue injury, and inadequate sample collection. In some cases, lesions may be difficult to access due to anatomical complexity, increasing procedural challenges and the possibility of non-diagnostic results. Sampling errors may occur if collected tissue does not accurately represent the targeted lesion, potentially requiring repeat procedures. These limitations can affect patient outcomes, increase healthcare costs, and delay treatment decisions. Manufacturers continue to develop technologies that improve targeting accuracy and tissue acquisition quality; however, ensuring consistent diagnostic performance across diverse clinical settings remains an ongoing challenge. Addressing these issues is critical for improving procedural success rates and patient confidence.

United States Biopsy Devices Market

The growing burden of cancer in the United States continues to drive demand for advanced diagnostic technologies, including biopsy devices. According to the American Association for Cancer Research, approximately 2.04 million new cancer cases and 618,120 cancer-related deaths were projected in the United States in 2025. The rising incidence of cancer highlights the increasing need for accurate and timely tissue diagnosis, supporting the adoption of minimally invasive biopsy procedures, image-guided biopsy systems, and advanced tissue sampling technologies across healthcare facilities. As early detection remains a critical component of cancer management, demand for biopsy devices is expected to remain strong throughout the country.

Canada Biopsy Devices Market

Canada's biopsy devices market is supported by increasing cancer awareness, expanding diagnostic services, and continued investments in healthcare modernization. The country's healthcare providers are increasingly adopting minimally invasive biopsy procedures to improve patient outcomes and reduce hospital stays. Growing emphasis on early cancer detection and personalized treatment planning is further contributing to market growth. Demand is particularly strong for breast, prostate, lung, and gastrointestinal biopsy procedures.

According to the Canadian Cancer Society, an estimated 247,100 Canadians were expected to be diagnosed with cancer in 2024. The rising number of cancer cases highlights the growing need for accurate tissue sampling and diagnostic technologies, supporting continued adoption of advanced biopsy devices across Canadian healthcare facilities.

Mexico Biopsy Devices Market

Mexico's biopsy devices market is expanding as healthcare providers increasingly focus on cancer screening, early diagnosis, and improved access to specialized diagnostic services. Growing awareness of cancer prevention, investments in hospital infrastructure, and the adoption of minimally invasive procedures are supporting demand for advanced biopsy technologies. Breast, colorectal, prostate, cervical, and lung cancers continue to generate substantial demand for tissue sampling and pathology-based diagnosis. In addition, modernization of healthcare facilities and greater utilization of image-guided procedures are contributing to market development. The country is also witnessing increased adoption of precision diagnostic approaches to support personalized treatment strategies.

According to INEGI, 95,237 deaths from malignant tumors were reported in Mexico during 2024, underscoring the need for effective cancer diagnosis and reinforcing demand for biopsy devices and related diagnostic technologies.

North America Biopsy Needles Market

The North America biopsy needles market represents a critical segment of the broader biopsy devices industry, driven by the increasing demand for minimally invasive tissue sampling procedures. Biopsy needles are widely used in the diagnosis of breast, lung, prostate, liver, and gastrointestinal cancers, enabling clinicians to obtain tissue samples for histopathological and molecular analysis. Rising cancer incidence, growing adoption of image-guided procedures, and advancements in needle design are supporting market growth. Manufacturers are developing biopsy needles with enhanced precision, improved tissue acquisition capabilities, and reduced patient discomfort. The expanding use of ultrasound-, CT-, and MRI-guided biopsies is further increasing demand for advanced needle technologies. As healthcare providers emphasize early cancer detection and precision diagnostics, biopsy needle utilization continues to grow across North America.

North America Lung Biopsy Devices Market

The North America lung biopsy devices market is expanding due to the rising prevalence of lung cancer and increasing adoption of minimally invasive diagnostic procedures. Lung biopsy devices are essential for obtaining tissue samples from suspicious pulmonary lesions, supporting accurate diagnosis and treatment planning. Growing utilization of CT-guided, bronchoscopic, and endobronchial ultrasound-guided biopsy procedures is improving access to difficult-to-reach lung nodules while reducing procedural risks. Advances in navigation technologies, robotic-assisted bronchoscopy, and precision tissue sampling systems are further enhancing diagnostic accuracy. Increasing implementation of lung cancer screening programs and greater awareness of early disease detection are contributing to market growth. As demand for personalized oncology treatments rises, high-quality lung tissue sampling remains a crucial component of cancer diagnosis throughout North America.

North America CT Scan Market

The North America CT scan market plays a vital supporting role in the biopsy devices industry by enabling accurate image-guided tissue sampling procedures. Computed tomography (CT) systems provide detailed cross-sectional imaging that assists clinicians in locating lesions and guiding biopsy needles with high precision. CT-guided biopsies are widely used for lung, liver, kidney, bone, and deep-tissue lesions that may be difficult to access through conventional methods. Increasing demand for minimally invasive diagnostic procedures and rising cancer screening activities are driving the use of CT imaging in biopsy workflows. Technological advancements such as low-dose imaging, real-time navigation, and enhanced image resolution continue to improve procedural outcomes. Growing reliance on image-guided diagnostics is strengthening the connection between CT imaging and biopsy device utilization across North America.

North America Hospitals Market

The North America hospitals market serves as the primary end-user segment for biopsy devices, accounting for a significant share of diagnostic and interventional procedures. Hospitals perform a large volume of biopsy procedures across oncology, pulmonology, gastroenterology, urology, and breast care departments, supported by advanced imaging infrastructure and specialized clinical expertise. Rising cancer incidence and increasing demand for early diagnosis are driving hospitals to invest in modern biopsy technologies, including automated biopsy systems, vacuum-assisted devices, and image-guided tissue sampling equipment. The growing adoption of precision medicine and molecular diagnostics is further increasing the need for high-quality tissue specimens obtained within hospital settings. As healthcare facilities expand diagnostic capabilities and minimally invasive procedure offerings, demand for biopsy devices within North American hospitals continues to rise.

North America Biopsy Device Market Segments:

Product

• Needle-Based Guns
• Biopsy Guidance Systems
• Biopsy Needles
• Biopsy Forceps
• Others

Application

• Breast Biopsy
• Lung Biopsy
• Prostate Biospy
• Liver Biopsy
• Gastroenterology Biopsy
• Others

Technology

• CT Scan
• Stereotactic Guided
• Ultrasound Guided
• MRI Guided
• Others

End User

• Hospitals
• Diagnostic & Imaging Center
• Others

Countries

• Canada
• United States
• Mexico
• Rest of North America

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis

• Cardinal Health, Inc.
• Hologic, Inc.
• Danaher Corporation
• Becton, Dickinson and Company
• Boston Scientific Corporation
• Medtronic plc.
• Olympus Corporation
• CONMED Corporation